Ignite Creation Date:
2024-05-06 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03439046
Status:
COMPLETED
Last Update Posted:
2024-02-23
First Post:
2018-01-29
Brief Title:
Study of the Molecular Features of Postmenopausal Women With HR HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and in Patients With a PIK3CA Mutation on Second-line Treatment With Alpelisib Plus Fulvestrant
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CLEE011AIT01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None